Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer

[1]  I. Bedrosian,et al.  Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status , 2012, Cancer.

[2]  L. Holmberg,et al.  Tumor stage affects risk and prognosis of contralateral breast cancer: results from a large Swedish-population-based study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Duffy,et al.  Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit , 2012, International journal of cancer.

[4]  A. Giuliano,et al.  Comparison of Patient Characteristics and Outcomes of Contralateral Prophylactic Mastectomy and Unilateral Total Mastectomy in Breast Cancer Patients , 2012, Annals of Surgical Oncology.

[5]  X. An,et al.  Comparison of clinicopathological characteristics and prognoses between bilateral and unilateral breast cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[6]  O. Olopade,et al.  Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers , 2011, British Journal of Cancer.

[7]  S. Narod.  The impact of contralateral mastectomy on mortality in BRCA1 and BRCA2 mutation carriers with breast cancer , 2011, Breast Cancer Research and Treatment.

[8]  Tong Wang,et al.  The risk factors and prognosis of bilateral primary breast cancer: a comparative study with unilateral breast cancer. , 2011, Oncology research.

[9]  M. Fernö,et al.  Prediction of outcome after diagnosis of metachronous contralateral breast cancer , 2011, BMC Cancer.

[10]  T. Sellers,et al.  Contralateral Prophylactic Mastectomy is Associated with a Survival Advantage in High-Risk Women with a Personal History of Breast Cancer , 2010, Annals of Surgical Oncology.

[11]  A. Stewart,et al.  Trends in Contralateral Prophylactic Mastectomy for Unilateral Cancer: A Report From the National Cancer Data Base, 1998–2007 , 2010, Annals of Surgical Oncology.

[12]  Hoda Anton-Culver,et al.  Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRCA2. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  I. Bedrosian,et al.  Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. , 2010, Journal of the National Cancer Institute.

[14]  S. Verhoef,et al.  Prophylactic Mastectomy in BRCA1 and BRCA2 Mutation Carriers: Very Low Risk for Subsequent Breast Cancer , 2010, Annals of surgery.

[15]  T. Tuttle,et al.  The Increasing Use of Prophylactic Mastectomy in the Prevention of Breast Cancer , 2010, Current oncology reports.

[16]  R. Arriagada,et al.  Relation of risk of contralateral breast cancer to the interval since the first primary tumour , 2009, British Journal of Cancer.

[17]  U. Bick,et al.  Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. John,et al.  Second primary breast cancer occurrence according to hormone receptor status. , 2009, Journal of the National Cancer Institute.

[19]  H. Kuerer,et al.  Predictors of contralateral breast cancer in patients with unilateral breast cancer undergoing contralateral prophylactic mastectomy , 2009, Cancer.

[20]  S. Duffy,et al.  Second breast cancers in a Tuscan case series: characteristics, prognosis, and predictors of survival , 2008, British Journal of Cancer.

[21]  Elisabeth G. E. de Vries,et al.  The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands , 2007, Breast Cancer Research and Treatment.

[22]  C. Isaacs,et al.  Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors , 2006, Breast Cancer Research and Treatment.

[23]  O. Olopade,et al.  Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: An update , 2006, International journal of cancer.

[24]  A. Howell,et al.  Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[25]  L. V. van't Veer,et al.  Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers , 2005, British Journal of Cancer.

[26]  J. Klijn,et al.  Selection bias influences reported contralateral breast cancer incidence and survival in high risk non-BRCA1/2 patients , 2005, Breast Cancer Research and Treatment.

[27]  Peter Cummings,et al.  Analysis of Matched Cohort Data , 2004 .

[28]  J. Satagopan,et al.  A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment , 2003, Breast Cancer Research.

[29]  T. Sellers,et al.  Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Andersen,et al.  Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. , 2000, American journal of surgery.

[31]  J. Peto,et al.  High constant incidence in twins and other relatives of women with breast cancer , 2000, Nature Genetics.

[32]  R. Thisted,et al.  The impact of contralateral breast cancer on the outcome of breast cancer patients treated by mastectomy. , 2000, Cancer journal.

[33]  N. Nagelkerke,et al.  Undertreatment of hypertension in a population‐based study in The Netherlands , 1998, Journal of hypertension.